ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年04月23日 10時00分
Source:
Eisai
エーザイ、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」に関する権利をRiemser社に譲渡
東京, 2018年04月23日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、非オピオイド系重度慢性疼痛治療薬「Prialt(R)」（一般名：ziconotide acetate、以下 「Prialt」）の欧州における独占的開発権および販売権を Riemser Pharma GmbH （本社：ドイツ ベルリン、CEO: Konstantin von Alvensleben、以下 Riemser 社）に対して譲渡する契約を締結しましたのでお知らせします。
本契約に基づき、当社は Riemser 社に対し、「Prialt」の欧州における独占的開発権および販売権を譲渡するとともに、契約一時金を受領します。
当社は、2006 年 2 月に、Elan Corporation PLC（当時）と締結した契約に基づき、本剤の欧州における開発・製造・販売の独占的権利を獲得し、非オピオイド系の髄腔内投与による重度慢性疼痛治療剤として、欧州で販売してきました。
Riemser 社は、欧州全域に拠点を持ち、がん、神経、感染症などのニッチ領域における医療用医薬品の販売、流通に強みを有するスペシャリティー・ファーマです。欧州市場に強い基盤を持つ Riemser社への権利譲渡は、欧州の重度慢性疼痛の患者様へのさらなる貢献を可能とするものです。
当社グループは、神経領域とがん領域を重点領域と位置づけており、これら領域の画新的新薬の開発の加速と地域特性に合致した最適なビジネスモデルの追求により、世界中の患者様とそのご家族の多様なニーズの充足とベネフィット向上により一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201835.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hokkaido Electric Power Corporation and Mitsubishi Corporation Establish a Joint Venture "Hokkaido Renewable Energy Aggregation Co., Ltd."
Mar 13, 2025 13:26 JST
Lexus Presents the World Premiere of the New "RZ"
Mar 12, 2025 17:45 JST
MHIET Achieves Rated Operation of a 6-Cylinder 500kW-class Hydrogen Engine Generator Set
Mar 12, 2025 14:11 JST
MOL and Fujitsu leverage AI for efficient crew replacement planning
Mar 12, 2025 13:53 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 10, 2025 20:24 JST
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Mar 10, 2025 12:10 JST
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 07, 2025 16:24 JST
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems
Mar 06, 2025 13:20 JST
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Mar 05, 2025 16:11 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 09:09 JST
MHI-MS Completes Domestic Development of Vehicle Transport Robot
Mar 04, 2025 19:39 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 17:22 JST
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
Mar 04, 2025 16:00 JST
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Mar 03, 2025 20:25 JST
Space Compass and NTT DOCOMO Successfully Demonstrate Data Connectivity to 4G Devices via HAPS at 20 km Above Kenya
Mar 03, 2025 20:14 JST
TOPPAN and DOCOMO Agree to Innovate Next-Generation 6G Services Using FEEL TECH Communication Technology
Mar 03, 2025 18:32 JST
More Latest Release >>
Related Release
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
More Press release >>